论文部分内容阅读
用马法兰和其他烷化剂抑制细胞生长治疗多发性骨髓瘤(MM)病人多数可以改善疼痛和其他症状,控制疾病进展,延长生存期。然而,经过30年使用不同烷化剂联合化疗后,MM的中位生存期仍然不超过36～48个月。早期研究显示,alfa干扰素对MM有良好的作用。干扰素对肿瘤负荷小及/或增生活性低的肿瘤患者,其疗效比晚期病例和高度恶性的病人好。如果这亦适用手MM,干扰素治疗MM的最佳效果可能是在对诱导治疗发生反应后和疾病的平顶期(Plateau Phase)。本研究评价了标准马法兰-强的松(MP)治疗有效后的MM病人是否可能通过持续的低剂量干扰
Inhibition of cell growth with melphalan and other alkylating agents Most patients with multiple myeloma (MM) improve pain and other symptoms, control disease progression and prolong survival. However, after 30 years of use of different alkylating agents in combination with chemotherapy, the median survival of MM remains less than 36 to 48 months. Early studies have shown that alfa interferon has a good effect on MM. Interferon is more effective than advanced and highly malignant tumors in tumor patients with low tumor burden and / or low proliferative activity. If this also applies to hand MM, the best effect of interferon in the treatment of MM may be after the induction therapy and the disease in the plateau phase (Plateau Phase). This study evaluated whether MM patients treated with standard melphalan-prednisone (MP) may be treated with sustained, low-dose interference